Speaker illustration

Doctor Annelie Shami

Lund University, Malmo (Sweden)

Following doctoral studies at Lund University, Sweden, examining atherogenesis through a matrix biology lens, and a 4 year post-doctoral fellowship at Prof. E. Lutgens’ laboratory at the University of Amsterdam, The Netherlands, investigating co-stimulatory molecules in atherosclerotic plaque progression, Annelie Shami has since her return to Lund University in 2019 developed a research profile combining these two specialties to explore immunoregulation of atherosclerotic plaque structure. Dr. Shami’s current focus is on three investigative paths: 1) The co-stimulatory dyad LIGHT/HVEM driving atherosclerotic plaque destabilization, 2) Mapping of plaque extracellular matrix (ECM) structure relative to plaque aggressiveness, and 3) The potential of ECM cleavage products in the circulation as biomarkers for cardiovascular disease.

Circulating LIGHT/TNFSF14 levels are negatively associated with cardiovascular mortality, while intra-plaque levels are associated with symptomatic cerebrovascular disease

Event: Frontiers in CardioVascular Biomedicine 2024

Topic: Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis

Session: Novel targets in atherosclerosis


LIGHT/TNFSF14 levels in carotid atherosclerotic plaques are associated with symptomatic cerebrovascular disease

Event: ESC Congress 2023

Topic: Pathophysiology and Mechanisms

Session: Saving the brain and the peripheral arteries


CD40 levels in plasma are associated with cardiovascular disease and in carotid plaques with a vulnerable plaque phenotype and remodelling

Event: ESC Congress 2020

Topic: Biomarkers

Session: The Plethora of Inflammatory Signals in Atherosclerosis


ESC 365 is supported by